Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the central nervous system biomarkers market?
The market for central nervous system biomarkers has expanded significantly in the past few years. The market valuation is forecasted to elevate from $5.58 billion in 2024 to $6.15 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.2%. This period of growth in the past can be credited to an increase in worries about neurological diseases, a high occurrence of central nervous system sicknesses, a surge in demand for improved diagnosis and treatment, advancements in healthcare facilities, and a growth in the elderly population.
What will be the central nervous system biomarkers market size in the future?
The market size for central nervous system biomarkers is anticipated to witness substantial growth in the coming years, expanding to $9 billion in 2029 with a compound annual growth rate of 10.0%. Factors contributing to the growth during the forecast period include the rising incidence of neurological disorders, an increasing demand for personalized medicine, an ageing population, an increased emphasis on early diagnosis, and the growing need for non-invasive diagnostic methods. The future trends for this period are set to be enhanced by new technological developments, strategic partnerships between biotech firms, pharmaceutical companies and other key players, an expansion in cerebrospinal fluid (csf) and blood-based biomarkers research, and the application of AI and machine learning algorithms.
Get your central nervous system biomarkers market report here!
What main drivers are fueling expansion in the central nervous system biomarkers market?
The anticipated increase in neurological disorders is predicted to drive the expansion of the central nervous system biomarker market. Neurological diseases involve a wide spectrum of conditions that impact the brain, spinal cord, and body nerves. These disorders can be caused by various factors such as genetics, infections, autoimmune reactions, degenerative conditions, tumors, vascular complications and physical injuries. Central nervous system (CNS) biomarkers in neurological diseases facilitate clinical diagnosis, establish disease risk or forecast, evaluate disease phase, and monitor the response to treatment. They hold a crucial role in comprehending these diseases and the prospect of their treatment. For example, the Centers for Disease Control and Prevention, a US-based government entity, reported in April 2023 that about 6.7 million Americans aged 65 and above were affected by Alzheimer’s disease. This figure is projected to nearly triple to 14 million by 2060. Additionally, the prevalence of the disease doubles in every interval of five years past the age of 65. Hence, the increase in neurological diseases catalyzes the expansion of the central nervous system biomarker market.
What key areas define the segmentation of the global central nervous system biomarkers market?
The central nervous system biomarkers market covered in this report is segmented –
1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types
2) By Disease: Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Other Diseases
3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications
4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users
Subsegments:
1) By Safety Biomarker: Toxicity Biomarkers, Adverse Event Biomarkers
2) By Efficacy Biomarker: Pharmacodynamic Biomarkers, Response Biomarkers
3) By Validation Biomarker: Predictive Biomarkers, Prognostic Biomarkers
4) By Other Types: Diagnostic Biomarkers, Biomarkers For Disease Progression
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12632&type=smp
Who are the dominant players expanding their reach in the central nervous system biomarkers market?
Major companies operating in the central nervous system biomarkers market include F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics
How are evolving market trends shaping central nervous system biomarkers Strategies?
The emergence of groundbreaking drug endorsements has become a principal trend in the central nervous system biomarker realm. To solidify their hold in the market, leading enterprises in the central nervous system biomarkers sector are striving to generate pioneering medications and secure approval. For example, Denovo Biopharma LLC, a US-based clinical-stage biopharmaceutical company, declared in January 2022 that the US Food and Drug Administration (FDA) had approved and greenlighted the company’s investigational new drug (IND) application of DB104 (liafensine) for treating treatment-resistant depression (TRD). This trial is the inaugural biomarker-guided global CNS investigation for TRD. This innovation could potentially help in identifying patients who are more likely to benefit from liafensine, thus promoting more individualized treatment choices. Liafensine is a unique substance that functions by escalating the levels of dopamine and norepinephrine in the brain.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12632
Which regions are emerging as leaders in the central nervous system biomarkers market?
North America was the largest region in the central nervous system biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Biomarkers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Renal Biomarkers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Systemic Lupus Erythematosus Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
